Immunological control of β-amyloid levels in vivo

Details Immunological control of β-amyloid levels in vivo Immunological control of β-amyloid levels in vivo

2003-03-10

2008-08-19

Saidha, Tekchand (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Catalytic antibody

C435S007920, C435S116000, C435S069100

Reexamination Certificate

active

07413884

ABSTRACT:
Disclosed are antibodies which catalyze hydrolysis of β-amyloid. Antibodies generated are characterized by the amide linkage which they hydrolyze. Methods of generating the antibodies by using β-amyloid peptides which incorporate transition state analogs are also provided. Also disclosed is a vectorized antibody which is characterized by the ability to cross the blood brain barrier, and is further characterized by the ability to catalyze the hydrolysis of β-amyloid. The vectorized antibody can take the form of bispecific antibody, which has a first specificity for the transferrin receptor and a second specificity for a taransition state adopted by β-amyloid hydrolysis.

REFERENCES:
patent: 5190865 (1993-03-01), Schultz
patent: 5439812 (1995-08-01), Benkovic et al.
patent: 5900237 (1999-05-01), Napper et al.
patent: 6043069 (2000-03-01), Koentgen et al.
patent: 6140091 (2000-10-01), Raso et al.
patent: 6294374 (2001-09-01), Sinha et al.
patent: 6329508 (2001-12-01), Friden
patent: 6702705 (2004-03-01), von Borstel et al.
patent: 6710226 (2004-03-01), Schenk
patent: 6743427 (2004-06-01), Schenk
patent: 6750324 (2004-06-01), Schenk et al.
patent: 2004/0081657 (2004-04-01), Schenk
patent: WO 99/06066 (1999-02-01), None
patent: WO 99/06536 (1999-02-01), None
patent: WO 99/27944 (1999-06-01), None
Janda, K.D., et al. (1991) Tetrahedron 47(14/15), 2503-2506.
Yu, J., et al. (1994) Angew. Chem. Int. Ed. Engl. 33(3), 339-340.
Tawfik, D.S., et al. (1994) Molecular Biotech. 1, 87-103.
Iazo et al. Protein sci. 2005, 1581-1596.
Hardy, J., Nature Genetics 1: 233-234 (1992).
Scheuner et al., Nature Med. 2: 864-870 (1996).
Kowall et al., Proc. Natl. Acad. Sci. USA 88: 7247-7251 (1991).
Gravina et al., J. of Biol. Chem. 270: 7013-7016 (1995).
Bickel et al., Proc. Natl. Acad. Sci. USA 90: 2618-2622 (1993).
Broadwell et al., Exp. Neurol. 142: 47-65 (1996).
Saito et al., Proc. Natl. Acad. Sci. USA 92: 10227-10231 (1995).
Pardridge et al., Pharmaceutical Res. 12: 807-816 (1995).
Descamps et al., Am. J. Physiol. 270: H1149-H1158 (1996).
Duffy and Pardridge, Brain Res. 420: 32-38 (1987).
Dehouck et al., J. Cell Biol. 138: 877-889 (1997).
Raso et al., J. Biol. Chem. 272: 27623-27628 (1997).
Mallander and Voss, J. Biol. Chem. 269: 199-206 (1994).
Kang and Pardridge, J. Pharm. Exp. Ther. 269:344-350 (1994).
Recht et al., J. Neurosurg. 72: 941-945 (1990).
Solomon et al., Proc. Natl. Acad. Sci. USA 94: 4109-4112 (1997).
Shin et al., Proc. Natl. Acad. Sci. USA 92: 2820-2824 (1995).

Affiliated with

Also associated with

Rating

Immunological control of β-amyloid levels in vivo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunological control of β-amyloid levels in vivo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunological control of β-amyloid levels in vivo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4016309